What We're Reading: Page 249
Industry reads hand-picked by our editors
Mar 07, 2019
-
The Wall Street Journal
Martin Shkreli Steers His Company From Prison—With Contraband Cellphone
-
Evaluate
The Gottlieb legacy: a surge in unproven treatments?
-
STAT
The mysterious dark money group behind a pharma-bashing ad campaign
-
JAMA Viewpoint
Prescription Drugs — List Price, Net Price, and the Rebate Caught in the Middle
Mar 06, 2019
-
Undark
For big pharma, a history of profiting from manufactured addiction
-
Genetic Engineering & Biotechnology News
Taking a new shot at tumor vaccines
-
The Wall Street Journal
A Doctor's Prescription for More AI in Medicine
-
Medical Marketing & Media
Meet pharma's digital chiefs
Mar 05, 2019
-
The New York Times
H.I.V. Is Reported Cured in a Second Patient, a Milestone in the Global AIDS Epidemic
-
Kaiser Health News
Big Pharma Gave Money To Patient Advocacy Groups Opposing Medicare Changes
-
Reuters
OxyContin maker Purdue Pharma exploring bankruptcy - sources
-
The Wall Street Journal
Celgene Odds Are in Investors' Favor
Mar 04, 2019
-
The New York Times
Drug Companies and Doctors Battle Over the Future of Fecal Transplants
-
Healthcare Dive
Mixing medicine and money: Why the rise of health system VCs is raising ethical concerns
-
The Economist
'Repurposing' off-patent drugs offers big hopes of new treatments
-
The Wall Street Journal
The Side Effects of Million-Dollar Drugs
Mar 01, 2019
-
The New York Times
Big pharma's hunt for new drugs is pushing up cost of deals
-
Axios
Pharma's research budgets are usually bigger than its profits
-
CNN
Newly discovered Alzheimer's genes further hope for future treatments
-
Endpoints
Pfizer’s blockbuster safety issue jumps the Atlantic as EMA launches its own review of Xeljanz
-
Kaiser Health News
Americans ready to crack down on drug prices that force some to skip doses
Feb 28, 2019
Feb 27, 2019
-
Evaluate
Adcom gives Karyopharm a second chance with selinexor
-
Reuters
Germany's Merck makes $5.9 billion counterbid for Versum
-
San Francisco Business Times
Big Pharma trims projects — and a potential $1 billion in payments — from collaboration with small Peninsula biotech
-
Kaiser Health News
Meow-ch! The $48,512 cat bite
Previous
